Up a notch

Why Cellestia Notch inhibitors could work in more patients than competitors’ do

By targeting a protein all Notch receptors use to turn on oncogenes, Cellestia Biotech AG’s molecules could treat more patients than therapies against individual Notch receptors or ligands, with less toxicity than other pan-Notch inhibitors.

The Notch family of receptors - NOTCH1, 2, 3 and 4 - have been linked to cancer via an array of mutations that either activate individual Notch receptors or ligands, or inactivate Notch repressors. Roughly half of T cell acute lymphoblastic leukemias, gastric cancers and melanomas

Read the full 809 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE